School of Pharmacy Current Research Publications Team Members E-mail Social Events

STRANGE Lab for GPcR Research

1	Gardner B, Hall DA and Strange PG (1996). Pharmacological analysis of stimulation of [^35S]GTPgS binding via human D2short and D2long dopamine receptors expressed in recombinant cells. Br J Pharmacol, 118, 1544-1550.
2	Strange PG (1996). The energetics of ligand binding to catecholamine receptors. Trends Pharmacol Sci, 17 235-271.
3	Vile J and Strange PG (1996) D2-like dopamine receptors are not detectable on human peripheral blood lymphocytes. Biol Psychiatry, 40, 881-885
4	Hoare SR and Strange PG (1996). Regulation of D2 dopamine receptors by amiloride and amiloride analogues. Mol Pharmacol, 50, 1295-1308.
5	Hall D and Strange PG (1997). Evidence that antipsychotic drugs are inverse agonists at D2 dopamine receptors. Brit J Pharmacol, 121, 731-736.
6	Gardner B, Hall DA and Strange PG (1997). Agonist action at D2 dopamine receptors: analysis of binding and functional parameters for the D2short dopamine receptor. J Neurochem, 69, 2589-2598.
7	Presland J and Strange PG (1998). Expression of D2 dopamine receptors in the yeast S.pombe. Biochem Pharmacol, 56, 577-582.
8	Welsh GI, Hall DA, Warnes A, Strange PG and Proud CG (1998). Activation of MAP kinase and p70S6 kinase by D2 dopamine receptors. J Neurochem, 70, 2139-2146.
9	Gardner B and Strange P.G. (1998) Agonist action at D2(long) dopamine receptors: ligand binding and functional assays. Brit J Pharmacol, 124, 978-984.
10	Tamimi NA, Stevens PE, O’Donnell PL, Strange PG, Muchaneta Kubara EC and El Nahas AM (1998) Expression of cytoskeletal proteins differentiates between progressors and non-progressors in treated idiopathic membranous nephropathy. Exp Nephrol, 6 217-225.
11	Tamimi NA, O’Donnell PJ, Muchaneta Kabara EC, Strange PG and El Nahas AM (1998) Renal myofibroblasts predict response to treatment in membranous nephropathy. Kidney International, 52 278-279.
12	Hall DA and Strange PG (1998) Comparison of the ability of dopamine receptor agonists to inhibit forskolin-stimulated cAMP accumulation via D2long and D3 receptors expressed in CHO cells. Biochem Pharmacol, 58, 285-289.
13	Hall DA and Strange PG (1999) Comparison of the ability of dopamine receptor agonists to inhibit forskolin-stimulated cAMP accumulation via D2long and D3 receptors expressed in CHO cells. Biochem Pharmacol ,58, 285-289.
14	Sartania N and Strange PG (1999) Role of conserved serine residues in the interaction of agonists with D3 dopamine receptors. J Neurochem, 72, 2621-2624.
15	Hooker AD, Green NH, Baines AJ, Bull AT, Jenkins N, Strange PG, James DC (1999) Constraints on the transport and glycosylation of recombinant IFN-gamma in Chinese hamster ovary and insect cells. Biotech Bioeng, 63, 559-572.
16	Strange PG (1999) G protein coupled receptors: conformations and states. Biochem Pharmacol 58, 1081-1088.
17	Coley C, Woodward R, Johansson AM, Strange PG and Naylor LH (2000) The effect of multiple serine/alanine mutations in TMV of the D2 dopamine receptor. J Neurochem ,74, 358-366.
18	McLoughlin D and Strange PG (2000) Mechanisms of agonism and inverse agonism at 5HT1A serotonin receptors. J Neurochem ,74, 347-357-366.
19	Hoare SR, Coldwell M, Armstrong D and Strange PG (2000). Allosteric regulation of D1, D2, D3 and D4 dopamine receptors. Brit J Pharmacol ,130, 1045-1059.
20	Malmberg A and Strange PG (2000). Site directed mutations in the third intracellular loop of the serotonin 5HT1A receptor alter G protein coupling from Gi to Gs in a ligand dependent manner. J Neurochem ,75, 1283-1293.
21	Strange PG (2000). Agonist binding to G protein coupled receptors. Brit J Pharmacol ,130, 820-821.
22	Strange PG (2001). Antipsychotic drugs: importance of dopamine receptors for mechanisms of therapeutic actions and side effects. Pharmacol Rev ,53, 119-133.
23	Wilson J, Lin H, Fu D, Javitch JA and Strange PG (2001). Mechanisms of inverse agonism of antipsychotic drugs at the D2 dopamine receptor: use of a mutant D2 dopamine receptor that adopts the activated conformation. J Neurochem ,77, 493-504.
24	Armstrong D and Strange PG (2001). Dopamine D2 receptor dimer formation: evidence from ligand binding J Biol Chem ,276, 22621-22629.
25	Cordeaux Y, Nickolls SA, Flood LA, Graber SG and Strange PG (2001). Agonist regulation of D2 dopamine receptor/G protein interaction: evidence for agonist selection of G protein subtype. J Biol Chem ,276, 28667-28675.
26	Mueller A, Kelly E and Strange (2002) Pathways for internalisation and recycling of the chemokine receptor, CCR5. Blood ,99, 785-791.
27	Mueller A, Mahmoud AG, Goedecke MC, McKeating JA and Strange PG (2002) Pharmacological characterisation of the chemokine receptor, CCR5. Brit J Pharmacol ,135, 1033-1043.
28	Strange PG (2002) Mechanisms of inverse agonism at G protein coupled receptors. Trends Pharmacol Sci ,23, 89-95.
29	Sarah L. Payne, Anette M. Johansson and Philip G. Strange (2002) Mechanisms of ligand binding and efficacy at the human D2(short) dopamine receptor. J Neurochem, 82, 1106-1117.
30	Gazi L, López-Giménez JF and Strange PG (2002) Formation of oligomers by G-protein-coupled receptors. Curr Op Drug Disc De, 5, 756-763.
31	Alder JT, Hacksell U and Strange PG (2003) Analysis of molecular determinants of affinity and relative efficacy of a series of R- and S-2-(dipropylamino)tetralins at the 5- HT1A serotonin receptor. Br J Pharmacol, 138, 1129-1139.
32	Gazi, L., Nickolls, S.A. and Strange, P.G. (2003) Functional coupling of the human dopamine D2 receptor with Gai1, Gai2, Gai3 and Gao G proteins: evidence for agonist regulation of G protein selectivity Br. J. Pharmacol, 138, 775-786.
33	Gazi L, Lopez-Gimenez JF, Rudiger MP and Strange PG (2003a) Constitutive oligomerization of human D2 dopamine receptors expressed in Spodoptera frugiperda 9 (Sf9) and in HEK293 cells. Analysis using co-immunoprecipitation and time-resolved fluorescence resonance energy transfer. Eur J Biochem 270(19):3928-3938.
34	Nickolls SA and Strange PG (2003) Interaction of the D2short dopamine receptor with G proteins: analysis of receptor/G protein selectivity. Biochem Pharmacol, 65, 1139-1150.
35	Gazi L, Wurch T, Lopez-Gimenez JF, Pauwels PJ and Strange PG (2003) Pharmacological analysis of a dopamine D(2Short):G(alphao) fusion protein expressed in Sf9 cells. FEBS Lett 545(2-3):155-160
36	Page NM, Bell NJ, Gardiner SM, Manyonda IT, Brayley KJ, Strange PG and Lowry PJ (2003) Characterization of the endokinins: human tachykinins with cardiovascular activity. Proc Natl Acad Sci U S A 100(10):6245-6250.
37	Roberts DJ, Lin H and Strange PG (2004) Investigation of the mechanism of agonist and inverse agonist action at D2 dopamine receptors. Biochem Pharmacol 67(9):1657-1665
38	Roberts DJ, Lin H and Strange PG (2004) Mechanisms of agonist action at D2 dopamine receptors. Mol Pharmacol 66(6):1573-1579
39	Bartfai T, Benovic JL, Bockaert J, Bond RA, Bouvier M, Christopoulos A, Civelli O, Devi LA, George SR, Inui A, Kobilka B, Leurs R, Neubig R, Pin JP, Quirion R, Roques BP, Sakmar TP, Seifert R, Stenkamp RE and Strange PG (2004) The state of GPCR research in 2004. Nature Reviews Drug Discovery 3(7):574-626
40	Mueller A and Strange PG (2004) Mechanisms of internalization and recycling of the chemokine receptor, CCR5. Eur J Biochem 271(2):243-252.
41	Mueller A and Strange PG (2004) CCL3, acting via the chemokine receptor CCR5, leads to independent activation of Janus kinase 2 (JAK2) and Gi proteins. FEBS Lett 570(1-3):126-132
42	Mueller A and Strange PG (2004) The chemokine receptor, CCR5. Int J Biochem Cell Biol 36(1):35-38
43	Nickolls SA and Strange PG (2004) The influence of G protein subtype on agonist action at D2 dopamine receptors. Neuropharmacology 47(6):860-872
44	Akam E and Strange PG (2004) Inverse agonist properties of atypical antipsychotic drugs. Biochem Pharmacol 67(11):2039-2045.
45	Bakker RA, Dees G, Carrillo JJ, Booth RG, Lopez-Gimenez JF, Milligan G, Strange PG and Leurs R (2004) Domain swapping in the human histamine H1 receptor. J Pharmacol Exp Ther 311(1):131-138
46	Roberts DJ and Strange PG (2005) Mechanisms of inverse agonist action at D2 dopamine receptors. Br J Pharmacol 145(1):34-42.
47	Strange PG (2005) Oligomers of D2 dopamine receptors: evidence from ligand binding. J Mol Neurosci 26(2-3):155-160.
48	Vivo M, Lin H and Strange PG (2005) Investigation of cooperativity in the binding of ligands to the D2 dopamine receptor. Mol Pharmacol.
49	Mueller A, Mahmoud NG and Strange PG (2006) Diverse signalling by different chemokines through the chemokine receptor CCR5. Biochem Pharmacol 72(6):739-748.
50	Lin H, Saisch SG and Strange PG (2006) Assays for enhanced activity of low efficacy partial agonists at the D(2) dopamine receptor. Br J Pharmacol 149(3):291-299.
51	Goggi JL, Sardini A, Egerton A, Strange PG and Grasby PM (2007) Agonist-dependent internalization of D2 receptors: Imaging quantification by confocal microscopy. Synapse 61(4):231-241.
52	Haworth B, Lin H, Fidock M, Dorr P and Strange PG (2007) Allosteric effects of antagonists on signalling by the chemokine receptor CCR5. Biochem Pharmacol 74(6):891-897.
53	Leach K, Charlton SJ and Strange PG (2007) Analysis of second messenger pathways stimulated by different chemokines acting at the chemokine receptor CCR5. Biochem Pharmacol 74(6):881-890.
54	Quirk K, Roberts DJ and Strange PG (2007) Mechanisms of G protein activation via the D2 dopamine receptor: evidence for persistent receptor/G protein interaction after agonist stimulation. Br J Pharmacol 151(1):144-152.
55	Strange P (2007) Not so good when 75% of grant applications fail. Nature 448(7149):22.
56	Strange PG (2007) Mechanisms underlying agonist efficacy. Biochem Soc Trans 35(Pt 4):733-736.
57	Strange P G (2008) Agonist binding, agonist affinity and agonist efficacy at G protein-coupled receptors. Br J Pharmacol published on line

School of Pharmacy | Current Research | Publications | Team Members | E-mail | Social Events